The combination product is the first to contain “a basal insulin with an ultralong duration of action, and a rapid-acting insulin in a single injection. The researchers conducted an open label study of 447 people with diabetes.
New Insulin Combo Degludec Reduces Hypo’s in Poorly Controlled Diabetes
Posted in Glucose & Insulin